Synthesis and cytotoxic activity of pyrazino[1,2-b]-isoquinolines, 1-(3-isoquinolyl)isoquinolines, and 6,15-iminoisoquino[3,2-b]-3-benzazocines

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 1, 2007, Pages 112-118

  González, Juan Francisco ^a   de la Cuesta, Elena ^a   Avendaño, Carmen ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Acyliminium cations; Antitumor agents; Cribrostatin 4; Phthalascidin; Tetrahydroisoquinolines

Indexed keywords

AMIDE; ANTINEOPLASTIC AGENT; BENZAZOCINE DERIVATIVE; CRIBROSTATIN 4; ISOQUINOLINE DERIVATIVE; PHTHALASCIDIN; RENIERAMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DRUG DETERMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGENOLYSIS; IN VITRO STUDY; PROTEIN DNA BINDING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

AZOCINES; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; ISOQUINOLINES; LUNG NEOPLASMS; MOLECULAR CONFORMATION; PYRAZINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 33750934767     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.10.009     Document Type: Article

References (22)

1. Scott J.D., and Williams R.M. Chem. Rev. 102 (2002) 1669-1730
2. Aune G.F., Furuta T., and Pommier Y. Anti-Cancer Drugs 13 (2002) 545-555
3. Corey E.J., Gin D.Y., and Kania R.S. J. Am. Chem. Soc. 118 (1996) 9202-9203
4. Endo A., Yanagisawa A., Abe M., Tohma Sh., Kan T., and Fukuyama T. J. Am. Chem. Soc. 124 (2002) 6552-6554
5. Cuevas C., Pérez M., Marti{dotless}́n M.J., Chicharro J.L., Fernández-Rivas C., Flores M., Francesch A., Gallego P., Zarzuelo M., de la Calle F., Garci{dotless}́a J., Polanco C., Rodri{dotless}́guez I., and Manzanares I. Org. Lett. 2 (2000) 2545-2548
6. Menchaca R., Marti{dotless}́nez V., Rodri{dotless}́guez A., Rodri{dotless}́guez N., Flores M., Gallego P., Manzanares I., and Cuevas C. J. Org. Chem. 68 (2003) 8859-8866
7. Zhou B., Edmonson S., Padrón J., and Danishefsky S.J. Tetrahedron Lett. 41 (2000) 2039-2042
8. Zhou B., Guo J., and Danishefsky S.J. Org. Lett. 4 (2002) 43-46
9. Marti{dotless}́nez E.J., Owa T., Schreiber S.L., and Corey E.J. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 3496-3501
10. Marti{dotless}́nez E.J., Corey E.J., and Owa T. Chem. Biol. 8 (2001) 1151-1160
11. Zewail-Foote M., and Hurley L.H. J. Am. Chem. Soc. 123 (2001) 6485-6495
12. Seeman F.C., and Hurley L.H. J. Am. Chem. Soc. 120 (1998) 13028-13041
13. Moore R.M., Seaman F.C., Wheelhouse R.T., and Hurley L.H. J. Am. Chem. Soc. 120 (1998) 2490-2491
14. Myers A.G., and Plowriht A.T. J. Am. Chem. Soc. 123 (2001) 5114-5115
15. We here apply the most general numbering system used in these alkaloids but we follow the IUPAC rules in Experimental Section.
16. Manzanares I., Cuevas I., Garci{dotless}́a-Nieto R., Marco E., and Gago F. Curr. Med. Chem. Anti-Cancer Agents 1 (2001) 257-276
17. Pettit G.R., Knight J.C., Collins J.C., Herald D.L., Pettit R.K., Boyd M.R., and Young V.G. J. Nat. Prod. 63 (2000) 793-798
18. Lane J.W., Estevez A., Mortara K., Callan O., Spencer J.R., and Williams R.M. Bioorg. Med. Chem. Lett. 16 (2006) 3180-3183
19. Liu Z., Wang Y., Tang Y., Chen S., Chen X., and Li H. Bioorg. Med. Chem. Lett. 16 (2006) 1282-1285
20. González J.F., de la Cuesta E., and Avendaño C. Tetrahedron 60 (2004) 6319-6326
21. González J.F., Salazar L., de la Cuesta E., and Avendaño C. Tetrahedron 61 (2005) 7447-7455
22. Boyd M.R., and Paull K.D. Drug Dev. Res. 34 (1995) 91-109